Brendinn Therapeutics

Company name

Brendinn Therapeutics


VU University Medical Center

The company

Brendinn Therapeutics focuses on restoring the brain endothelial dysfunction that underlies neurological diseases. They have identified epigenetic modulators (microRNAs) that directly improve brain endothelial function and have therapeutic potential. Brendinn Therapeutics is now developing its unique and proprietary microRNAs prior to clinical evaluation in neurological diseases.

Brendinn Therapeutics is focused on developing solutions for neurological disorders in which blood-brain barrier dysfunction plays a role. Their focus is on progressive multiple sclerosis. Other indications for future research are vascular dementia, stroke, traumatic brain injury, Parkinson’s disease and amyothrophic lateral sclerosis.